Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury
Kidney360 · 2026-03 · 7 (3) · 527-534
DOI: 10.34067/kid.0000001024 ↗At a glance
Multizentrische Studie in Kidney360, published online on 2025-11-20. Written by Yuenting Diana Kwong and 13 co-authors. Institution: Division of Nephrology, University of California San Francisco, San Francisco, California. Major MEDLINE topics: Acute Kidney Injury, Proteinuria, Renal Insufficiency, Chronic, Albuminuria. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Kaiser Permanente, Michigan Institute for Clinical and Health Research, NIDDK NIH HHS.
Abstract (original language)
Key Points Quantifying albuminuria 3 months after AKI predicts future risk of kidney disease progression but is often not completed. In a cohort of 554 patients with CKD, urine protein-to-creatinine ratio measured within 1 year after AKI had robust prognostic value. Testing of total proteinuria beyond 3 months after AKI among patients with CKD identified those at risk of kidney disease progression.
Background
Expert consensus recommends quantifying albuminuria 3 months after hospitalized AKI to identify patients at risk for kidney disease progression, but testing is often not completed in clinical practice. We evaluated the utility of testing total proteinuria (which is less expensive than albuminuria) and on a less rigid time schedule after AKI to facilitate its adoption into clinical practice.
Methods
Prospective multicenter cohort study of patients with CKD who were hospitalized with AKI between 2013 and 2021. Urine protein-to-creatinine ratio (PCR) was assessed per research protocol within 1 year of hospital discharge. Cox proportional hazard models were applied with a focus on C-statistics as the primary metric regarding post-AKI PCR's ability to discriminate risk of kidney disease progression as defined by halving of eGFR or ESKD.
Results
Five hundred and fifty-four Chronic Renal Insufficiency Cohort participants (43% female, 51% non-Hispanic Black, mean eGFR 43 ml/min per 1.73 m 2 ) had PCR measurements within a year of AKI hospital discharge (82% stage 1 AKI). The median PCR, obtained 147 median (interquartile range, 79-233) days after AKI, was 0.36 mg/g (interquartile range, 0.12–1.37 mg/g). Over the mean follow-up of 2.6 years, 124 participants had kidney disease progression. Higher post-AKI PCR was associated with increased risk of kidney disease progression (hazard ratio, 2.99 for each doubling of proteinuria; 95% confidence interval, 2.54 to 3.52; C-statistic, 0.80). An adjusted model including demographic and clinical risk factors had high discrimination for kidney disease progression (C-statistic, 0.86). Renin-angiotensin system inhibitors use decreased after AKI, especially among patients with higher AKI stage and lower eGFR.
Conclusions
Proteinuria evaluation by PCR within 1 year after AKI hospital discharge may be a feasible and flexible option for risk-stratifying survivors at higher risk of subsequent kidney function loss. We also identified opportunities to optimize management of proteinuria after AKI.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Nephrology, University of California San Francisco, San Francisco, California.
- Division of Nephrology, Department of Medicine, University of Maryland Medical Center, Baltimore, Maryland.
- Division of Nephrology, University of New Mexico, Albuquerque, New Mexico.
- Department of Kidney Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.
- Division of Research, Kaiser Permanente Northern California, Pleasanton, California.
- Department of Medicine, Tulane University, New Orleans, Louisiana.
ORCID profiles: Yuenting Diana Kwong, Ian E McCoy, Matthew R Weir, Hernan Rincon-Choles, Alan S Go, L Lee Hamm, Jing Chen, Jesse Y Hsu, Xiaoming Zhang, Chi-Yuan Hsu
Funding
- Kaiser Permanente
- Michigan Institute for Clinical and Health Research
- NIDDK NIH HHS
- University of Illinois at Chicago
- Tulane University
- Perelman School of Medicine, University of Pennsylvania
- School of Medicine, University of New Mexico
- Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University
Cite
APA
Kwong, Y. D., Liu, K. D., McCoy, I. E., Muiru, A. N., Weir, M. R., Unruh, M. L., Rincon-Choles, H., Go, A. S., Hamm, L. L., Chen, J., Hsu, J. Y., Zhang, X., Hsu, C. Y., & CRIC Study Investigators (2026). Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury. Kidney360, 7(3), 527-534. https://doi.org/10.34067/kid.0000001024
Vancouver
Kwong YD, Liu KD, McCoy IE, Muiru AN, Weir MR, Unruh ML, et al. Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury. Kidney360. 2026;7(3):527-534. doi:10.34067/kid.0000001024
BibTeX
@article{Kwong2026,
author = {Kwong, Yuenting Diana and Liu, Kathleen D and McCoy, Ian E and Muiru, Anthony N and Weir, Matthew R and Unruh, Mark L and Rincon-Choles, Hernan and Go, Alan S and Hamm, L Lee and Chen, Jing and Hsu, Jesse Y and Zhang, Xiaoming and Hsu, Chi-Yuan and CRIC Study Investigators, CRIC Study Investigators},
title = {Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury},
journal = {Kidney360},
year = {2026},
volume = {7},
number = {3},
pages = {527--534},
doi = {10.34067/kid.0000001024}
}
EUVIMED